Inactive Matrix Gla Protein and Cardiovascular Outcomes: the Multi-Ethnic Study of Atherosclerosis
Abstract Body (Do not enter title and authors here): Background: Matrix Gla protein (MGP) inhibits arterial calcification. Higher inactive MGP, dephosphorylated-uncarboxylated (dp-ucMGP), is positively associated with vascular calcification, possibly portending cardiovascular events. The objective was to determine the association of dp-ucMGP with incident cardiovascular disease (CVD) events and mortality in the Multi-Ethnic Study of Atherosclerosis (MESA). Methods: MESA is a cohort study of 45-84 year-old individuals enrolled between 2000-02 with adjudicated outcomes through 2019. Dp-ucMGP was measured at baseline in n=2663 participants with cardiac computed tomography at Exams 1 (2000-02) and 5 (2010-12). Using age-stratified Cox proportional hazard models, adjusted for sex, race-ethnicity, body mass index, systolic blood pressure, statin use, anti-hypertensive medication use, smoking status, physical activity, alcohol use, diabetes, high density lipoprotein, low density lipoprotein, triglycerides, phosphate, and estimated glomerular filtration rate, we determined the association of dp-ucMGP with risk of all CVD (mean follow-up 16 + 4 years), hard CVD (17 + 3 years), hard CHD (17 + 3 years), and all-cause mortality (18 + 2 years). Results: The youngest age quartile (45-53-years-old) with higher dp-ucMGP levels (520-2934 pmol/L) had an increased risk of all CVD (HR 3.01 [95% CI 1.56, 5.80], p=0.001), hard CVD (HR 2.78 [95% CI 1.29, 6.02], p=0.009), hard CHD (HR 3.37 [95% CI 1.29, 8.81], p=0.013) and all-cause mortality (HR 2.69 [95% CI 1.06, 6.79], p=0.037) compared to dp-ucMGP levels between 150-519 pmol/L in maximally adjusted models. There was no relationship with any outcomes for the other age quartiles (Table). Conclusions: Middle aged individuals with elevated dp-ucMGP levels (>520 pmol/L) had an increased risk of incident CVD, CHD, and all-cause mortality.
Berlot, Ashley
( Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Bortnick, Anna
( WEILER HOSP
, Bronx
, New York
, United States
)
Fu, Xueyan
( TUFTS UNIVERSITY
, Boston
, Massachusetts
, United States
)
Shea, Kyla
( TUFTS UNIVERSITY
, Boston
, Massachusetts
, United States
)
Tracy, Russell
( UNIVERSITY VERMONT
, Colchester
, Vermont
, United States
)
Budoff, Matthew
( LUNDQUIST INSTITUTE
, Torrance
, California
, United States
)
Kim, Ryung
( Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Naveed, Mahim
( San Francisco VA
, San Francisco
, California
, United States
)
Booth, Sarah
( Tufts University
, Boston
, Massachusetts
, United States
)
Kizer, Jorge
( San Francisco VA
, San Francisco
, California
, United States
)
Author Disclosures:
Ashley Berlot:DO NOT have relevant financial relationships
| Anna Bortnick:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):Getinge, Honoraria to Institution:Past (completed)
; Research Funding (PI or named investigator):Amgen:Active (exists now)
; Research Funding (PI or named investigator):CSL Behring:Past (completed)
; Other (please indicate in the box next to the company name):Zoll, Honoraria to Institution:Past (completed)
| Xueyan Fu:DO NOT have relevant financial relationships
| Kyla Shea:DO NOT have relevant financial relationships
| Russell Tracy:No Answer
| Matthew Budoff:DO have relevant financial relationships
;
Researcher:General Electric:Active (exists now)
| Ryung Kim:No Answer
| Mahim Naveed:DO NOT have relevant financial relationships
| Sarah Booth:No Answer
| JORGE KIZER:DO have relevant financial relationships
;
Individual Stocks/Stock Options:Abbott:Past (completed)
; Individual Stocks/Stock Options:Pfizer:Past (completed)
; Individual Stocks/Stock Options:Merck:Past (completed)
; Individual Stocks/Stock Options:Medtronic:Past (completed)
; Individual Stocks/Stock Options:Lilly:Past (completed)
; Individual Stocks/Stock Options:Johnson & Johnson:Past (completed)
; Individual Stocks/Stock Options:Bristol Myers Squibb:Past (completed)
; Individual Stocks/Stock Options:AbbVie:Past (completed)